Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks

John Carroll

Editor & Founder

A biotech in China reports today that it will be scooping up a string of preclinical siRNA programs from Sanofi as the multinational player laterals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

What will pharma's share buyback shopping spree mean for M&A?

Vertex operations chief Stuart Arbuckle to retire

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Low-pro­file start­up stakes its claim to Sanofi's siR­NA plat­form in wake of set­backs

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks